The Vector is a new executive publication created specifically for senior life sciences leaders across commercial, market access, HEOR, and medical affairs. Unlike most industry newsletters, this isn’t a recap of headlines or policy updates. Instead, we leverage RPR, our stakeholder engagement solution, to capture unique insights that we can share with senior industry professionals. Please get in touch if you’d like to learn more about this research or how our experts can help support your own.
The Vector
Strategic Intelligence for Life Science Executives
The LATEST issue
How will EU General Pharmaceutical Legislation (GPL) impact
orphan medicine development and assessment?
In our third issue, we asked 15 payers across France, Germany, Italy, Spain and the UK how the EU General Pharmaceutical Legislation will reshape orphan medicine development, assessment and launch. European payers reveal where the new framework creates pressure, what evidence will win, and why the decisions that matter most are moving earlier than many manufacturers expect. We learn the following:
- Why breakthrough status invites scrutiny, not a premium: how payers plan to negotiate differently with higher-tier orphan products
- The evidence hierarchy that payers will reward: what most strengthens an orphan value story when randomized trials aren’t feasible
- A country-by-country view: why France is the most skeptical market, Spain the most polarized, Italy the most positive, and why the UK could become an early-launch market for rare diseases
- The policy collision ahead: how US MFN pricing and EU reform pull launch decisions in opposite directions, and why the next 12–24 months matter
Access Vector 3
Our second issue
Could Most Favored Nation (MFN) Pricing
Reshape Global Launch Strategy?
In our second issue, we surveyed 33 payers across 11 non‑US markets to understand how renewed US interest in Most‑Favored‑Nation (MFN) drug pricing could reshape pricing, reimbursement, and access globally. Specifically, we asked payers about their views on:
- Expected impact on national drug pricing and access
- Anticipated manufacturer response and the implications on payer decision-making
- Country-level spillover on new product launches and impact on launch sequencing and delays
Access Vector 2
Our first issue
Is AI Beginning to Shape Coverage Decision Workflows?
For the inaugural issue, we surveyed and engaged US payers directly to understand how they are thinking about AI right now:
- How do they currently use AI?
- How quickly are they moving to adopt it for what other uses?
- How manufacturers can prepare for success?
Access Vector Issue 1
Headquarters:
HOBOKEN
221 River Street, 9th Floor
Hoboken, New Jersey 07030, US
